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Abstract
The liver performs critical physiological functions, including metabolizing and re-
moving substances, such as toxins and drugs, from the bloodstream. Hepatotoxicity
itself is intimately linked to abnormal hepatic transport and hepatotoxicity remains the
primary reason drugs in development fail and approved drugs are withdrawn from the
market. For this reason, we propose to analyze, across liver compartments, the trans-
port kinetics of fluorescein–a fluorescent marker used as a proxy for drug molecules–
using intravital microscopy data. To resolve the transport kinetics quantitatively from
fluorescence data, we account for the effect that different liver compartments (with
different chemical properties) have on fluorescein’s emission rate. To do so, we develop
ordinary differential equation transport models from the data where the kinetics are
related to the observable fluorescence levels by ”measurement parameters” that vary
across different liver compartments. On account of the steep non-linearities in the
kinetics and stochasticity inherent to the model, we infer kinetic and measurement
parameters by generalizing the method of parameter cascades. For this application,
the method of parameter cascades ensures fast and precise parameter estimates from
noisy time traces.
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INTRODUCTION
Physiological Context of Hepatotoxicity
Liver transport is a fundamental physiological process whose significance to human health has
increased with the proliferation of pharmaceuticals and environmental toxins.1–3 Since the
liver is a primary venue for the clearance of xenobiotics, it is particularly susceptible to drug-
induced injury, in a process known as hepatotoxicity.4–6 Drug hepatotoxicity is associated
with inhibition of hepatic transport 7–9 through the inhibition of transporters.10,11 Drug
effects on hepatic transporters are also a major cause of drug-drug interactions, compromising
drug safety and complicating drug dosing.12 Although hepatic side effects are a primary
focus of preclinical drug evaluations, drug-induced liver injury affects an estimated million
people each year globally, and is the most common cause for withdrawal of drugs from the
market.13,14
Typically, the effects of a drug on hepatic transport are first evaluated outside animal
models such as in studies of vesicle preparations or cultured cells.15 While these simplified
systems yield accurate kinetic transport parameters, they also have key limitations: 1) they
do not recapitulate the complexity of typical clinical situations, which may include one or
more pathological conditions in an individual taking a combination of drugs;16 and 2) they
lack the pharmacokinetic processes that determine drug distributions, confounding prediction
of in vivo drug effects from in vitro dose-response curves.17,18 In other words, they lack the
full complexity of in vivo transport, a non-vectorial process mediated by the simultaneous
activity of multiple transporters.19,20
By contrast, laboratory animals, combined with the tools of intravital microscopy (IVM)
data,21 provide the necessary physiological context.22 The failure to predict drug transport
inside the liver from IVM data, however, highlights fundamental shortcomings in how we
exploit the data. In principle, the data contains information on the mechanism of vectorial
drug transport involving different transporters, often with overlapping specificities. Imaging
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methods also, simultaneously, are poised to provide spatial and temporal resolution on how
drugs might impact liver transport from their point of uptake into hepatocytes, through
secretion into the bile, with secretion back into the blood, or flow in the biliary tract.23,24
Recently, some studies have used IVM21,25,26 to monitor transport kinetics of sodium
fluorescein27,28 and identify the effects of chronic kidney disease on organic anion transport.29
While rich in structure, the IVM data also presents important challenges toward achieving
a complete picture of fluorescein’s transport kinetics as it evolves from the liver capillaries
(sinusoids) into the cytosol of the hepatocytes (uptake) and then into the bile canaliculi
(canalicular secretion), from which they are cleared into the bile. However, fluorescein’s
emission is deeply dependent on its local chemical environment. That is, the fluorescence
signal from these probes is sensitive to environmental quenching30,31 and fluorescein itself
may exist in multiple forms, e.g., glucuronidated form,30 across liver compartments.
Thus, in this study, we combine experiments and theory to develop a quantitative method
to analyze hepatic transport from fluorescence time measurements using IVM data. In par-
ticular, we model the kinetics of hepatic transport, in other words the kinetics of transport of
fluorescent species, using a set of ordinary differential equations (ODEs).32–37 We treat the
units of fluorescing species in a particular compartment and their kinetics between liver com-
partments as a hidden (latent) variables and introduce measurement parameters to describe
the relationship between the absolute concentrations and fluorescence intensity in different
observed regions. We calibrate our ODE model, i.e., infer kinetic and measurement parame-
ters, from noisy fluorescence time traces obtained from IVM using the method of parameter
cascades.38
Mathematical Methods of ODE Parameter Estimation
A number of parameter estimation methods exist39–50 some of which we have recently re-
viewed.51,52 Here, we adapt the method of parameter cascades38 which is computationally
efficient, maintains good numerical efficiency for estimation of ODE parameters from data
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,53 works for linear or nonlinear dynamics, straightforwardly estimates measurement param-
eters and takes simultaneous advantage of all points in a time trace to perform parameter
inference.54 Using this method, ODE solutions are approximated using spline coefficients.
These coefficients are estimated with penalized smoothing splines with a roughness penalty
term.
MATERIALS AND METHODS
Experimental Methods
Here we used quantitative IVM data for transport in the liver of rats with 5/6th nephrectomy
(5/6N)55,56 where hepatic drug transport is impacted by chronic kidney disease.29,56 This
data was previously published and information on 5/6N rat models and IVM data collection
is detailed in Refs.29 and.21
ODE Model and Parameter Estimation
We begin with a set of ODEs describing the evolution in time, t, of a species vector, x, of
length m whose elements are units of fluorescence in a particular compartment
x˙(t) = f(x, t|θ). (1)
In particular, the species coincide with different chemical forms of fluorescein, i.e., mod-
ified by being glucuronidated,30 and unmodified forms in each compartment. The vector θ
contains parameters (kinetic rates describing transport parameters between liver compart-
ments) whose values are a priori unknown. The vector, x itself is not directly observed.
Rather, we supplement the dynamical model above with the following measurement model
y(t) = Hx(t) + (t) (2)
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where y(t) is a noisy vector of length r describing total units of fluorescence measurements
in each compartment at time t and  describes the noise associated with the measurement
assumed white noise with zero mean and finite variance (σ2). H is an m × n measurement
matrix in the measurement equation, Eq. (2), which relates the state to the measurement
output similar to an equivalent matrix appearing in Kalman filtering.57 Each element of H
is called a measurement parameter. For example, a measurement parameter of 0.15 indicates
that only 15% of the substrate is observed, while the remaining 0.85 is unobserved. It
naturally follows that all measurement parameters take values between [0, 1]. We define a
vector of all measurement and kinetic parameters, called structural parameters, θ′ = {θ,H}
and assume that the variances associated with the noise are, a priori, known.
Next, we use the method of parameter cascades38 to learn the parameters from the
data. To do so, we first approximate the solution, x(t), of the ODE, Eq. (1), with a linear
combination of K basis functions, Φ = {ϕk}, k=1,..., K, as follows
x̂i =
K∑
k=1
cikϕk ⇒ x̂ = cΦ (3)
where x̂ is the approximation of the curve x in terms of our linear expansion. We use i
to iterate over the m species in our model and call the expansion coefficients cik nuisance
parameters. The basis functions must themselves approximate the ODE solutions. We se-
lected B-splines as these basis functions allow us to appropriately control solution smoothness
across time as warranted by the data which serves as input.41,53 The number of basis func-
tions must be large enough to adequately represent x58 and the function x̂i must be learned
by optimizing a global objective function that, at once, satisfies the ODE and adequately
fits the noisy data.59 We then iterate between two optimization routines until a pre-specified
criterion for the global optimum is met. In the first optimization step, the nuisance param-
eters, c, are estimated using a smoothing ODE-penalized criterion, in a process known as
inner optimization. Within the inner optimization, the structural parameters are kept fixed
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and the nuisance parameters are fitted to data by minimizing the following penalized sum
of squares.
Jin(c|θ′,λ,y) =
n∑
i=1
|yi − x̂i|2 + λPEN(x̂). (4)
In the inner optimization, the regularization parameter, λ, controls the trade off between
fitting the data and fidelity to the ODEs for each xi. Intuitively, for larger noise, as defined
by Eq. (2), we need larger λ as the data themselves become less reliable.
In the outer optimization step, the structural parameters, θ′, are updated by minimizing
the following sum of squared errors between the data yi and our estimates x̂i
Jout(θ
′|λ,y) =
n∑
i=1
|yi − x̂i|2. (5)
Here Jout(θ
′|λ,y) is minimized with respect to θ′ by using the Newton-Raphson method.
The following pseudo-code (further detailed in Supplementary Information Appendix A)
sketches this procedure.
Algorithm 1
procedure
Set a value for λ
Pick initial values for ĉ, θ̂
′
Inner optimization loop:
Estimate ĉ by minimizing Jin(ĉ
′|θ′,λ)
given by Eq. (4)
Outer optimization loop:
Estimate θ̂
′
by minimizing Jout(θ
′|y,λ)
given by Eq. (5)
if θ̂
′
are changed (to within some preset precision), Jin(ĉ
′|θ′,λ) is reoptimized with
respect to ĉ then goto Inner optimization.
else θ̂
′
= θ′ .
close;
To be clear, we explicitly include measurement parameters among the structural param-
eters. The ability to incorporate measurement parameters constitutes an important gener-
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alization of the method of cascades to deal with noisy data that was previously suggested.38
We highlight here that the method of cascades is an important, fast and general alternative
to extended Kalman filters or other Kalman filter variants.60–62 Kalman filters may solve
similar problems to that above but may suffer in the case of pronounced non-linearities in
the dynamics, i.e., Eq. (1). This is especially relevant to us here as we would like our method
to hold for a broad range of non-linear dynamics.63,64
In the Supplementary Information Appendix B, we describe in greater detail how confi-
dence intervals of parameters estimates are determined. Briefly, here we mention that if the
data are poor or data sets are too small for the number of parameters to be estimated, the
global objective function may be flat around its maximum and unable to sharply discrimi-
nate between different parameter values (a problem known as ”weak identifiability”65,66). By
contrast, ”structural unidentifiability” arises when model parameters are not independent
and different parameter choices result in equally good fits.67
In our case by using a method drawn from Ref.,68 we identified which structural param-
eter(s) are unidentifiable and input their values from other sources before estimating other
parameters. To do this, we used an approach proposed in Ref.69 detailed in the Supplemen-
tary Information Appendix B.
Method Validation
To test our method, we validate its performance on systems of increasing complexity using
sets of simulated (i.e., synthetic) data, where the ground truth is known.
1- Two States System: In the simplest example, we have started with a Two States
(compartments or pixels) model whose (Markov) kinetics are determined by two transition
rates. Fig. (1) illustrates this simple two states Markov model.
The linear ODEs describing this system are
8
X1 X2
k+
k-
Figure 1: Schematic of Two States Markov Model. Here, we have two rates, k+ and
k−, corresponding to these two states.

dX1
dt
= −k+X1 + k−X2
dX2
dt
= k+X1 − k−X2
(6)
with measurements
yX1
yX2
 =
α 0
0 β

X1
X2
+
1
2
 (7)
where θ′ = [k+, k−, α, β] being the unknown structural parameter vector. The mean of both
1 and 2 is zero and the variance of both is assumed known, i.e., the measurement noise
assumed Gaussian is fixed in a pre-calibration step. To resolve structural unidentifiability
(see the Supplementary Information Appendix B), we must specify either α or β. For
concreteness, we presume that from other experiments, it is known that α = 0.5 and thus
we are left with 3 unknown parameters.
The solutions to Eqs. (6) and (7) are plotted in Fig. (2) for parameter values [0.5, 2, 0.5, 0.3]
and known initial conditions [yX1(0), yX2(0)] = [0, 1].
We also tested the accuracy of our approach by adding white noise with different vari-
ances, namely 0.05, 0.1 and 0.2, to our simulated data. In Fig. (2) and Table (1), we show
the results of our fitting and parameter estimation.
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Figure 2: Fits for the Synthetic Model Shown in Fig. (1). For each compartment the
results are shown after adding white noise with variance 0.05 (A), 0.1 (B) and 0.2 (C). The
dots are generated data points, the dash lines are theoretical curves, and the solid lines are
the fits on our data. AU here stands for arbitrary units.
2- Generalized Two States System: We continue testing our approach by generalizing the
previous example. That is, we have two de-coupled sets of ODEs for the dynamics whose
outputs are coupled by measurement. That is, we have

dX1
dt
= −k+X1 + k−X2
dX2
dt
= k+X1 − k−X2
(8)
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Table 1: Two State Results. The results of parameter estimation for the two state
system captured in Fig. (1) with and without considering noise (the rates are in
units of min−1). The standard deviations reported for the structural parameters
are taken from one representative run after determining these parameters over
multiple runs of a given synthetic data set.
k+ k− β
Without Noise
0.5 2.0 0.3 True values
0.5000 2.0000 0.3000 Estimated values
0.0001 0.0002 0.0001 Standard deviation
σ2 = 0.05 for the Noise
0.5 2.0 0.3 True values
0.4555 1.9854 0.3120 Estimated values
0.0466 0.2809 0.0206 Standard deviation
σ2 = 0.1 for the Noise
0.5 2.0 0.3 True values
0.5202 2.2808 0.3185 Estimated values
0.0180 0.1434 0.0650 Standard deviation
σ2 = 0.2 for the Noise
0.5 2.0 0.3 True values
0.5582 1.7767 0.3381 Estimated values
0.1134 0.3351 0.1266 Standard deviation

dX ′1
dt
= −k′+X ′1 + k′−X ′2
dX ′2
dt
= k′+X
′
1 − k′−X ′2
(9)
and
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yX1
yX2
 =
α 0 α′ 0
0 β 0 β′


X1
X2
X ′1
X ′2

+
1
2
 . (10)
The above reflects, for example, two different fluorescent species (the primed and un-
primed) hopping between two compartments (subscripted one and two). Measurements on
both compartments reveal the total amount of fluorescent material in each compartment but
does not discriminate between the primed and unprimed.
The structural parameter vector here is θ′ = [k+, k−, k′+, k
′
−, α, β, α
′, β′]. To eliminate
structural unidentifiability, using the procedure highlighted earlier, we specify α = 0.5 and
α′ = 0.25. The solutions to Eqs. (8)-(10) are plotted in Fig. (3) for parameter values
[0.3, 0.5, 2.0, 4.0, 0.5, 0.5, 0.25, 0.15] and initial conditions [yX1(0), yX2(0)] = [0, 1]. The noise,
1 and 2, is treated as we did earlier.
We test the accuracy of our approach by considering white noise with different variances
(0.05, 0.1 and 0.2) added to our simulated data. In Fig. (3) and Table (2) we show the results
of our fitting and parameter estimation with and without noise.
3- FitzHugh-Nagumo Model : Finally, we tested our method with one of the best known
models, developed by FitzHugh70 and Nagumo et al.71 to examine the behavior of spike
potentials in the giant axon of squid neurons. While this model is dissimilar in structure to
our hepatic transport model, the FitzHugh-Nagumo model, shown below, is often used as a
benchmark in ODE parameter estimation problems38,72

dV
dt
= c(V − V
3
3
+R)
dR
dt
=
1
c
(V − a+ bR).
(11)
This system describes the mutual dependency between voltage across an axon membrane,
12
BC
A
Figure 3: Fits for Generalized Two States Systems. For each compartment the results
of adding white noise with variance 0.05 (A), 0.1 (B) and 0.2 (C) have been shown. The
dots are generated data points, dash lines are theoretical curves, and the solid lines are the
fits on our data.
V , and a recovery variable R summarizing outward currents. In this case we setup simulated
data for parameter values [a, b, c] = [0.2, 0.2, 3] and initial conditions [V (0), R(0)] = [−1, 1].
In addition to the above, we supplement the dynamical model with a measurement model
yV
yR
 =
α 0
0 β

V
R
+
1
2
 . (12)
Thus, the parameters to be determined are now θ′ = [a, b, c, α, β]. Identifiability demands
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Table 2: Generalized Two States Results. The results of parameter estimation
for generalized two states with and without considering noise (the rates are in
units of min−1). See Table (1) for details on the standard deviation.
k+ k− k′+ k
′
− β β
′
Without Noise
0.3 0.5 2.0 4.0 0.5 0.15 True values
0.2991 0.5000 2.0012 4.0001 0.5000 0.1501 Estimated values
0.0023 0.0001 0.0016 0.0004 0.0008 0.0005 Standard deviation
σ2 = 0.05 for the Noise
0.3 0.5 2.0 4.0 0.5 0.15 True values
0.3055 0.5101 2.0192 4.0501 0.4938 0.1471 Estimated values
0.0234 0.0005 0.0737 0.0403 0.0062 0.0043 Standard deviation
σ2 = 0.1 for the Noise
0.3 0.5 2.0 4.0 0.5 0.15 True values
0.2795 0.4316 1.7738 4.2755 0.5729 0.1421 Estimated values
0.1064 0.1884 0.1348 0.1229 0.1261 0.1087 Standard deviation
σ2 = 0.2 for the Noise
0.3 0.5 2.0 4.0 0.5 0.15 True values
0.1993 0.6909 1.7047 3.2478 0.4247 0.1967 Estimated values
0.1231 0.1983 0.1801 0.1293 0.1129 0.0915 Standard deviation
that we specify either α or β. For this reason, here we set α = 0.5. For synthetic data
generated using [0.2, 0.2, 3.0, 0.5, 0.75] and initial conditions [V (0), R(0)] = [−1, 1], the results
are shown in Fig. (4) and Table (3).
As expected across all models, increasing the noise variance level decreases our parameter
estimation accuracy and robustness (i.e., error bar). The amount by which increased noise
reduces the accuracy and robustness of our estimates depends on the model under consider-
ation. So much is clear by comparing, with a variance of 0.2 for the white noise, the results
from Fig. (1) to those of Fig. (4).
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Figure 4: Fit to the FitzHugh-Nagumo Model Supplemented by a Measurement
Model. As before, we consider the following different noise variance levels: 0.05 (A), 0.1
(B) and 0.2 (C). Details in text.
RESULTS
Full Hepatic Transport Model
We now construct a model of hepatic transport. Transport in the liver consists of fluorescein
transport between and through sinusoid blood vessels, into the hepatocytes and then into
the canaliculi.21 The data we have collected consists of fluorescence intensity from fluorescein
in all three compartments.
To construct our model, we: 1) assume no direct transport between sinusoid and canalicu-
lus; and 2) assume only three compartments (sinusoid, hepatocyte and canaliculus). In this
15
Table 3: FitzHugh-Nagumo Model Results. The results of parameter estimation
for the FitzHugh-Nagumo model obtained by considering increasing noise as
before (the rates are in units of min−1). See Table (1) for details on the standard
deviation.
a b c β
Without Noise
0.2 0.2 3 0.75 True values
0.2001 0.1999 3.0001 0.7500 Estimated values
0.0001 0.0013 0.0032 0.0001 Standard deviation
σ2 = 0.05 for the Noise
0.2 0.2 3 0.75 True values
0.2005 0.1995 3.0020 0.7498 Estimated values
0.0012 0.0016 0.0160 0.0018 Standard deviation
σ2 = 0.1 for the Noise
0.2 0.2 3 0.75 True values
0.1895 0.1841 3.046 0.7702 Estimated values
0.0114 0.0280 0.0243 0.0124 Standard deviation
σ2 = 0.2 for the Noise
0.2 0.2 3 0.75 True values
0.1543 0.2317 2.9056 0.6924 Estimated values
0.0189 0.0372 0.0662 0.0726 Standard deviation
case, we designate fluorescein species in the sinusoid, hepatocyte and canaliculus as S(t),
H(t), and C(t) respectively. In full generality, we also consider back flow from the hepato-
cyte back into the sinusoid.
We treat fluorescein in each compartment as a different species with a different mea-
surement parameter since each compartment presents variable quenchers species and con-
centrations (e.g., binding proteins reducig fluorescein net emission).21 What is more, we
consider two forms of fluorescein, both unmodified and glucuronidated as it is known that
the majority of fluorescein is glucuronidated within 30 minutes of intravenous injection.30
A schematic of the model is provided in Fig. (5). In our model, the species vector, previ-
ously written as x in Eq. (1), includes the unit of measurement for unmodified and modified
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(glucuronidated) fluorescein in each compartment. The quantities are given by S,H,C for
fluorescein and S ′, H ′, C ′, for glucuronidated fluorescein in each compartment. Finally, while
we have six species, glucuronidated and unmodified fluorescein in three compartments, we
only have three measurements, namely the fluorescence intensity in each compartment.
𝒌𝑺→𝑯 , 𝒌′𝑺→𝑯
𝒌𝑯→𝑺 , 𝒌′𝑯→𝑺 𝒌𝑯→𝑪 , 𝒌′𝑯→𝑪 𝒌𝑪 , 𝒌′𝑪𝒌𝑯𝑻
S(t)
H(t)
C(t)
Figure 5: Schematic of Hepatic Transport Model Used. We consider five transport
rates for fluorescein: kS→H for the transport from sinusoid to the hepatocyte, kH→S from
the hepatocyte back to the sinusoid, kH→C from the hepatocyte to the canaliculus, and a
loss rate kC from the canaliculus. We also assume glucuronidated fluorescein is transported
via the same mechanisms, albeit with rates that have different values, designated by the
primed symbols above. Finally kHT represents the transformation of fluorescein into its
glucuronidated form within the hepatocyte. The arrows show the direction of flow.
Based on the model schematic provided in Fig. (5), after pre-specifying the input rate
into the sinusoid thereby setting initial conditions, the dynamical model is given by
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
dS
dt
= −kS→HS + kH→SH
dH
dt
= kS→HS − (kH→S + kH→C)H − kHTH
dC
dt
= kH→CH − kCC
(13)
and

dS ′
dt
= −k′S→HS ′ + k′H→SH ′
dH ′
dt
= k′S→HS
′ − (k′H→S + kH→C)H ′ + kHTH
dC ′
dt
= k′H→CH
′ − k′CC ′.
(14)
The measurement model is now

yS
yH
yC
 =

α 0 0 α′ 0 0
0 β 0 0 β′ 0
0 0 γ 0 0 γ′


S
H
C
S ′
H ′
C ′

+

1
2
3
 . (15)
The parameters α, β, and γ and their primes are our measurement parameters for un-
modified and glucuronidated fluorescein in each compartment. We note that, in this case,
the measurement matrix H is no longer square or diagonal; at any given time, we have fewer
measurements than number of species in our model.
Furthermore, just as we did with simulated data, we used the identifiability problem
procedure (detailed in the Supplementary Information Appendix B) and, on this basis, pre-
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specified the values for the measurement parameters of both fluorescein and glucuronidated
fluorescein in the sinusoid, α = 0.5 and α′ = 0.25, and also the conversion rate between them
in the hepatocyte, kHT = 0.5 min
−1.
Study on Sham Control and 5/6N Rat Model of Chronic Kidney
Disease
Here, we used IVM data from 5/6N rat models as these are often used as models for the
study of chronic kidney disease.73 To evaluate the functional outcomes of the 5/6N model
on hepatic transport, we collected IVM data29 in the liver of sham control operated rats
Fig. (6A). In this case, sham control operated rats were treated with the same anesthetic
and surgical procedures without kidney removal (as opposed to 5/6N with kidneys removed).
The results for these studies are shown in Tables (4) and (5). Similar to previously
published work, e.g.,29 our results also show a meaningful change in hepatic transport in
5/6N as compared to the sham control. Concretely, our analysis reveals that the 5/6N,
when compared to the sham control operated rats, exhibited a decrease rate of hepatic
uptake of fluorescein. Put differently, we anticipate differences in kS→H , kH→S, k′S→H , and
k′H→S between these two cases, as hepatic transport is impaired in the 5/6N rat.
Table 4: Experimental Results Using Sham Control Operated Rats. Parameter
estimates for the experimental data Fig. (6A) (the rates are in units of min−1).
kS→H kH→S kH→C kC k′S→H k
′
H→S k
′
H→C k
′
C β γ β
′ γ′
2.2440 2.1501 0.1726 0.3802 0.6744 2.5368 1.5433 0.9639 0.4731 0.1393 0.1340 0.3763 Mean values
0.1678 0.1082 0.1007 0.0963 0.1324 0.0751 0.1035 0.2076 0.0995 0.1179 0.0514 0.0985 Standard deviation
To resolve model unidentifiability, we pre-specify kHT as well as the measurement pa-
rameters α and α′ in our model. We chose kHT and those two parameters as their values
are the easiest to determine via physiological experiments74–76 or via fluorescence lifetime
imaging.77 Our quantitative conclusions are insensitive to exact parameter estimates used
initially for kHT , α and α
′.
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Table 5: Experimental Results Using 5/6N Rat Models of Chronic Kidney Dis-
ease. Parameter estimates for the experimental data Fig. (6B) (the rates are in
units of min−1).
kS→H kH→S kH→C kC k′S→H k
′
H→S k
′
H→C k
′
C β γ β
′ γ′
2.0661 2.2067 0.1580 0.2753 0.5385 2.1169 1.4519 0.6943 0.6285 0.2305 0.5092 0.2564 Estimated values
0.1558 0.0592 0.0347 0.0997 0.1527 0.0372 0.2725 0.2617 0.0590 0.0218 0.0334 0.0125 Standard deviation
Effect of Taurolithocholate
In the previous subsection, we devised a control to assess the functional consequences of the
5/6N and recovered a change in transport rates from the sinusoid to the hepatocyte. Now,
we look at different treatment controls using Taurolithocholate (TLC) treated rats.29 TLC
is a pharmaceutical agent that inhibits transport from the hepatocyte to the canaliculus and
out from the canaliculus, so we expect these relevant rates to decrease.
TLC-induced cholestasis is a common experimental model for drug-induced cholesta-
sis.78–80 According to previous work, TLC impairs hepatic transport81 and also significantly
blocks hepatocyte uptake of sodium fluorescein.80 Thus, by using TLC treated rat models,
we could evaluate our method to see how well it works in estimating transport rates from
the hepatocyte to the canaliculus and transport rates from canaliculus out.
The result of blocking hepatocyte uptake of sodium fluorescein using TLC treated rat
on hepatocyte is shown in Fig. (6C). The estimated ODE parameter values for this data set
appear in Table (6) where we note the blocking effect TLC has on secretions to and from
the canaliculus recovered by our model as measured by the small values for the rates kH→C
and kC .
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Figure 6: Results of Studies of Fluorescein Transport in Rat Model Sham Control,
5/6N, and Taurolithocholate (TLC) Treated Livers. In (A) we have sample images
from a set of collected images from the liver of a rat as the sham control (without removing
the kidneys) during intravenous injection of sodium fluorescein. On the right hand side we
see our method’s fit to the data with kinetic parameters responsible for the fit reported in
Table 4. In (B) we show results for a 5/6N rat model in which the kidneys were removed. The
main difference between (A) and (B) is the change in the rate of hepatic uptake of fluorescein
as quantified by the rates from the sinusoid to the hepatocyte between the sham control and
5/6N rats for both glucuronidated and unglucuronidated forms of fluorescein. More details
on the rat model are provided in Ref.29 In (C) we show example images collected from a rat
treated by the agent TLC obtained after intravenous injection. The TLC highly reduces the
rate of fluorescein uptake into the canaliculus.
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Table 6: Experimental Results Using TLC. The results of parameter estimation
for the experimental data Fig. (6C) (the rates are in units of min−1).
kS→H kH→S kH→C kC k′S→H k
′
H→S k
′
H→C k
′
C β γ β
′ γ′
1.6657 0.9180 0.0032 0.0026 3.3125 1.8065 1.0885 0.8773 0.2158 0.7079 0.1042 0.7474 Estimated values
0.0212 0.0332 0.0008 0.0005 0.0695 0.0800 0.0158 0.0286 0.0172 0.0502 0.0112 0.0407 Standard deviation
The kHT , α, and α
′ were prespecified for the same reasons as for the Sham Control and
5/6N Rat cases above.
DISCUSSION AND CONCLUSIONS
Drug development is a long and costly endeavor; the average drug costs nearly a billion
dollars and takes roughly 15 years to bring to market.82,83 Given these costs and timescales,
it is critical to identify the efficacy and risks associated with a candidate drug early in the
development process. Clearly improving the prediction of drug failures could substantially
reduce development costs.83,84 The need for improved tools for preclinical evaluation of drugs
is the central focus of the FDA’s Critical Path Initiative.85 Although new drugs are scru-
tinized for effects on liver function, adverse effects on the liver comprise the most common
biological reason for drug failure in the development of new pharmaceuticals86,87 and the
most common cause for withdrawal of drugs from the market.12 The failure to predict these
problems reflects fundamental shortcomings in the methods that are used in preclinical drug
studies.
Our long-term goal is to combine mathematical modeling with IVM experimental data to
determine the effects of drugs on hepatic transport. The theoretical framework we develop
here provides more accurate and reproducible measures of transport, including pathways
that cannot be observed by other methods, supporting more powerful studies of in vivo
liver function. By specifically addressing problems tied to fluorescence measurement, our
approach could increase the physiological relevance of in vivo studies in ways that could
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impact preclinical evaluations of the hepatic drug effects thereby extending the predictive
power of in vitro drug development studies, minimizing the numbers of animals needed for
in vivo studies and reducing the number of drug failures. As a first step towards developing
new methods for the estimation of in vivo transport rate parameters, we have presented an
implementation of the known method of parameter cascades for ODE parameter estimation,
one that we tailored to IVM experimental data on hepatic transport.
In the context of Biophysics, parameter inference methods have a comparatively long
history.88–96 The goal of parameter estimation is to find unknown parameters of the model
that give the best fit to a set of experimental data.97 While a number of methods tailored to
learning parameters from ODEs exist, many of them require that the ODEs be numerically
solved39,40 which entails expensive computation and requires knowing the initial values of the
ODE variables. However, efficient computational methods exist that do not require actually
solving the ODEs numerically.41–43 A drawback for many of these methods is that they do
not take into account errors approximation when making parameter inferences, which causes
the well-known bias problem.44 On the other hand, we deal with these problems through
parameter cascades by defining two nested levels of optimization in our adaptation. In the
inner optimization loop, we estimated nuisance parameters (coefficients of basis function).
Then structural parameters are estimated in the outer optimization loop.
Disadvantages of our method include the fact that weight assigned to the penalty term
(the regularization parameter) can impact overall inference if unreasonable values are se-
lected.98 This is true for any Bayesian inference problem as well if unusual hyperparameters
are selected57 Furthermore, we only determine point estimates, rather than full posterior
distributions, over the unknown parameter values.99–106
Regarding other approaches which focus on parameter estimation such as maximum
likelihood and Bayesian mehods,107,108 naive implementations demand that ODEs be solved
first.101,104,109 Here with parameter cascades, this step is unnecessary even for highly non-
linear dynamics (as exemplified by the FitzHugh-Nagamo results). On account of its ability
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to deal with non-linear dynamics as well as measurement parameters, our method should be
general enough to deal with non-linearities introduced, say, by having kinetics dictated by
Michaelis-Menten ODE forms for all reactions. The latter would be especially relevant to
capturing transporter saturation if such information is discernible from the data.
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,53 works for linear or nonlinear dynamics, straightforwardly estimates measurement param-
eters and takes simultaneous advantage of all points in a time trace to perform parameter
inference.54 Using this method, ODE solutions are approximated using spline coe cients.
These coe cients are estimated with penalized smoothing splines with a roughness penalty
term.
MATERIALS AND METHODS
Experimental Methods
Here we used quantitative IVM data for transport in the liver of rats with 5/6th nephrectomy
(5/6N)55,56 where hepatic drug transport is impacted by chronic kidney disease.29,56 This
data was previously published and information on 5/6N rat models and IVM data collection
is detailed in Refs.29 and.21
ODE Model and Parameter Estimation
We begin with a set of ODEs describing the evolution in time, t, of a species vector, x, of
length m whose elements are units of fluorescence in a particular compartment
x˙(t) = f(x, t|✓). (1)
In particular, the species coincide with di↵erent chemical forms of fluorescein, i.e., mod-
ified by being glucuronidated,30 and unmodified forms in each compartment. The vector ✓
contains parameters (kinetic rates describing transport parameters between liver compart-
ments) whose values are a priori unknown. The vector, x itself is not directly observed.
Rather, we supplement the dynamical model above with the following measurement model
y(t) = Hx(t) + ✏(t) (2)
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